Sino Biopharmaceutical (SBMFF) Ratios
Sino Biopharmaceutical Ratios
SBMFF's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, SBMFF's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.37 | 1.26 | 1.05 | 1.29 | 1.53 |
| Quick Ratio | 1.28 | 1.14 | 0.96 | 1.17 | 1.41 |
| Cash Ratio | 0.48 | 0.49 | 0.42 | 0.43 | 0.63 |
| Solvency Ratio | 0.10 | 0.20 | 0.13 | 0.14 | 0.68 |
| Operating Cash Flow Ratio | 0.37 | 0.34 | 0.27 | 0.31 | 0.35 |
| Short-Term Operating Cash Flow Coverage | 1.10 | 0.86 | 0.54 | 0.65 | 0.82 |
| Net Current Asset Value | $ 555.92M | $ 2.05B | $ -1.63B | $ -185.83M | $ 688.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.21 | 0.15 | 0.20 | 0.22 | 0.20 |
| Debt-to-Equity Ratio | 0.52 | 0.31 | 0.41 | 0.47 | 0.40 |
| Debt-to-Capital Ratio | 0.34 | 0.23 | 0.29 | 0.32 | 0.29 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.06 | 0.03 | 0.12 | 0.15 |
| Financial Leverage Ratio | 2.48 | 2.05 | 2.09 | 2.15 | 2.00 |
| Debt Service Coverage Ratio | 0.68 | 0.70 | 0.53 | 0.59 | 2.62 |
| Interest Coverage Ratio | 25.65 | 20.79 | 11.68 | 13.01 | 16.46 |
| Debt to Market Cap | 0.16 | 0.19 | 0.17 | 0.18 | 0.14 |
| Interest Debt Per Share | 0.91 | 0.58 | 0.56 | 0.77 | 0.66 |
| Net Debt to EBITDA | 0.52 | 0.04 | 0.45 | 0.80 | 0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 82.07% | 81.51% | 80.95% | 82.76% | 80.15% |
| EBIT Margin | 19.76% | 17.91% | 22.54% | 21.69% | 70.29% |
| EBITDA Margin | 23.57% | 21.16% | 26.64% | 25.71% | 73.99% |
| Operating Profit Margin | 21.84% | 21.26% | 22.08% | 21.46% | 18.91% |
| Pretax Profit Margin | 21.81% | 18.28% | 20.65% | 20.04% | 69.14% |
| Net Profit Margin | 7.36% | 12.12% | 8.90% | 9.77% | 54.38% |
| Continuous Operations Profit Margin | 16.69% | 16.57% | 17.61% | 17.36% | 61.85% |
| Net Income Per EBT | 33.75% | 66.32% | 43.10% | 48.78% | 78.66% |
| EBT Per EBIT | 99.85% | 86.01% | 93.50% | 93.36% | 365.71% |
| Return on Assets (ROA) | 3.08% | 5.35% | 3.67% | 3.97% | 24.13% |
| Return on Equity (ROE) | 7.64% | 10.95% | 7.65% | 8.55% | 48.23% |
| Return on Capital Employed (ROCE) | 13.68% | 13.38% | 14.11% | 12.72% | 11.24% |
| Return on Invested Capital (ROIC) | 8.98% | 10.39% | 9.45% | 9.02% | 8.77% |
| Return on Tangible Assets | 3.40% | 5.61% | 3.72% | 4.09% | 24.83% |
| Earnings Yield | 2.34% | 6.71% | 3.28% | 3.38% | 17.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.79 | 5.76 | 5.70 | 5.60 | 6.27 |
| Payables Turnover | 3.81 | 3.56 | 3.74 | 3.08 | 2.97 |
| Inventory Turnover | 2.53 | 2.25 | 2.50 | 2.49 | 2.75 |
| Fixed Asset Turnover | 3.11 | 2.81 | 2.64 | 2.81 | 3.15 |
| Asset Turnover | 0.42 | 0.44 | 0.41 | 0.41 | 0.44 |
| Working Capital Turnover Ratio | 4.42 | 9.12 | 7.50 | 3.73 | 2.68 |
| Cash Conversion Cycle | 124.75 | 123.28 | 112.22 | 93.15 | 68.02 |
| Days of Sales Outstanding | 76.16 | 63.38 | 64.03 | 65.12 | 58.23 |
| Days of Inventory Outstanding | 144.37 | 162.32 | 145.82 | 146.67 | 132.64 |
| Days of Payables Outstanding | 95.79 | 102.43 | 97.63 | 118.64 | 122.85 |
| Operating Cycle | 220.54 | 225.71 | 209.85 | 211.79 | 190.87 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.51 | 0.38 | 0.26 | 0.34 | 0.29 |
| Free Cash Flow Per Share | 0.42 | 0.30 | 0.19 | 0.24 | 0.19 |
| Dividend Paid and CapEx Coverage Ratio | 2.90 | 2.04 | 2.60 | 2.11 | 1.89 |
| Capital Expenditure Coverage Ratio | 5.46 | 4.74 | 3.56 | 3.67 | 2.83 |
| Operating Cash Flow Coverage Ratio | 0.58 | 0.68 | 0.48 | 0.45 | 0.44 |
| Operating Cash Flow to Sales Ratio | 0.29 | 0.23 | 0.23 | 0.24 | 0.20 |
| Free Cash Flow Yield | 7.57% | 10.01% | 6.14% | 6.07% | 4.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 42.70 | 14.90 | 30.45 | 29.54 | 5.71 |
| Price-to-Sales (P/S) Ratio | 3.15 | 1.81 | 2.71 | 2.89 | 3.11 |
| Price-to-Book (P/B) Ratio | 3.27 | 1.63 | 2.33 | 2.53 | 2.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 13.21 | 9.99 | 16.28 | 16.48 | 24.04 |
| Price-to-Operating Cash Flow Ratio | 10.79 | 7.88 | 11.71 | 11.99 | 15.55 |
| Price-to-Earnings Growth (PEG) Ratio | 1.42 | 0.10 | -1.08 | -0.34 | 0.01 |
| Enterprise Value Multiple | 13.88 | 8.57 | 10.62 | 12.03 | 4.33 |
| Enterprise Value | 104.11B | 52.37B | 74.13B | 80.47B | 85.98B |
| EV to EBITDA | 13.88 | 8.57 | 10.62 | 12.03 | 4.33 |
| EV to Sales | 3.27 | 1.81 | 2.83 | 3.09 | 3.20 |
| EV to Free Cash Flow | 13.72 | 10.03 | 17.00 | 17.65 | 24.76 |
| EV to Operating Cash Flow | 11.20 | 7.92 | 12.22 | 12.84 | 16.02 |
| Tangible Book Value Per Share | 1.94 | 2.30 | 1.59 | 1.93 | 1.92 |
| Shareholders’ Equity Per Share | 1.70 | 1.85 | 1.30 | 1.60 | 1.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.09 | 0.15 | 0.13 | 0.11 |
| Revenue Per Share | 1.76 | 1.67 | 1.12 | 1.40 | 1.43 |
| Net Income Per Share | 0.13 | 0.20 | 0.10 | 0.14 | 0.78 |
| Tax Burden | 0.34 | 0.66 | 0.43 | 0.49 | 0.79 |
| Interest Burden | 1.10 | 1.02 | 0.92 | 0.92 | 0.98 |
| Research & Development to Revenue | 0.19 | 0.18 | 0.17 | 0.17 | 0.14 |
| SG&A to Revenue | 0.41 | 0.42 | 0.07 | 0.08 | 0.08 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.34 | 0.95 | 1.02 | 1.08 | 0.29 |
Currency in CNY